Symptom clusters and symptom interference of HCC patients undergoing TACE: A cross-sectional study in China

Supportive Care in Cancer

Volumn 21, Issue 2, 2013, Pages 475-483

  Cao, Wenting ^a   Li, Juan ^a   Hu, Chen ^a   Shen, Jie ^a   Liu, Xiangyan ^a   Xu, Yan ^a   Ye, Zhixia ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Symptom cluster; Symptom interference; Transcatheter arterial chemoembolization (TACE)

Indexed keywords

ADULT; AGED; ARTICLE; CHEMOEMBOLIZATION; CHINA; CROSS-SECTIONAL STUDY; DAILY LIFE ACTIVITY; DECREASED APPETITE; DEPRESSION; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DISTRESS SYNDROME; DYSPNEA; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; JAUNDICE; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MOOD; NAUSEA; PARESTHESIA; PREVALENCE; PRIORITY JOURNAL; SATISFACTION; SLEEP DISORDER; SYMPTOM; SYMPTOM ASSESSMENT; SYMPTOM CLUSTER; SYMPTOM INTERFERENCE; VOMITING; WEIGHT REDUCTION; WORK;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CHINA; CLUSTER ANALYSIS; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PALLIATIVE CARE; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; SYNDROME; YOUNG ADULT;

EID: 84874114367     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-012-1541-5     Document Type: Article

References (25)

1. Steel JL, Carr BI, Olek MC et al (2007) Health-related quality of life in patients diagnosed with hepatobiliary carcinoma. US Gastroenterol Rev Issue II:87-90
2. Khan SA, Taylor-Robinson SD, Toledano MB et al (2002) Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol 37:806-813
3. Bruix J, Sherman M, Llovet JM et al (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35:421-430
4. Bruix J, Llovet JM (2002) Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 35:519-524
5. Llovet JM, Bru C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19(3):329-338
6. Llovet JM, Di Bisceglie AM, Bruix J et al (2008) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100:698-711
7. Forner A, Reig ME, de Lope CR et al (2010) Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 30:61-74
8. Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37:429-442
9. Llovet JM, Real MI, Montana X et al (2002) Arterial embolization or chemoembolization versus systemic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 359:1734-1739
10. Miraglia R, Pietrosi G, Maruzzelli L et al (2007) Efficacy of transcatheter embolization/chemoembolization (TAE/TACE) for the treatment of single hepatocellular carcinoma. World J Gastroenterol 13(21):2952-2955
11. Ryder SD (2003) Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut 52(Suppl 3):iii1-iii8
12. Zhao GS, Yang XH, Li C et al (2010) Application of gelatin sponge particles to the interventional treatment of hepatic carcinoma. Zhongguo Xin Yao Za Zhi 19(17):1571-1574
13. Li RH, Liu XD, Lu CY (2011) Complications of transarterial chemoembolization (TACE) for liver cancer. Shi Yong Yi Xue Za Zhi 26(1):163
14. Liu YG, Jin L, Wang L et al (2011) Clinical observation and nursing in interventional therapy of liver cancer. Zhonghua Quan Ke Yi Xue Za Zhi 9(2):309-311
15. Kim H, McGuire DB, Tulman L et al (2005) Symptom clusters: concept analysis and clinical implications for cancer nursing. Cancer Nurs 28:270-282
16. Ryu Eunjung, Kim K, Cho MS et al (2010) Symptom clusters and quality of life in Korean patients with hepatocellular carcinoma. Cancer Nurs 33(1):3-10
17. Yount S, Cella D, Webster K et al (2002) Assessment of patient-reported clinical outcome in pancreatic and other hepatobiliary cancers: the FACT hepatobiliary symptom index. J Pain Symptom Manag 24(1):32-44
18. Sahara S, Kawai N, Sato M et al (2012) Prospective evaluation of transcatheter arterial chemoembolization (TACE) with multiple anti-cancer drugs (Epirubicin, Cisplatin, Mitomycin C, 5-Fluorouracil) compared with TACE with Epirubicin for treatment of hepatocellular carcinoma. Cardiovasc Interv Radiol. doi: 10.1007/s00270-012-0352-x
19. Meng MB, Wen QL, Cui YL et al (2011) Meta-analysis: traditional Chinese medicine for improving immune response in patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. Explore 7(1):37-43
20. Xie F, Zang J, Guo X et al (2012) Comparison of transcatheter arterial chemoembolization and microsphere embolization for treatment of unresectable hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol 138(3):455-62
21. Wang XS, Wang Y, Guo H et al (2004) Chinese version of the M.D. Anderson Symptom Inventory: validation and application of symptom measurement in cancer patients. Cancer 101:1890-1901
22. Barsevick AM, Dudley W, Beck S et al (2004) A randomized clinical trial of energy conservation for patients with cancer-related fatigue. Cancer 100(6):1302-1310
23. Kim HJ, Barsevick AM, Lorraine T et al (2008) Treatment-related symptom clusters in breast cancer: a secondary analysis. J Pain Symptom Manag 36(5):468-479
24. Kim JE, Dodd MJ, Aouizerat BE et al (2009) A review of the prevalence and impact of multiple symptoms in oncology patients. J Pain Symptom Manag 37(4):715-736
25. Barsevick AM (2007) The concept of symptom cluster. Semin Oncol Nurs 23(2):89-98